Menu
Advancing next-generation targeted radiotherapies to improve outcomes in cancer patients.
Convergent Therapeutics Announces FDA Clearance of IND Application for CONV01-α, a Best-in-Class Radioantibody Targeting Prostate-Specific Membrane Antigen
Advancing next-generation targeted radiotherapies to improve outcomes in cancer patients.
Convergent Therapeutics Announces FDA Clearance of IND Application for CONV01-α, a Best-in-Class Radioantibody Targeting Prostate-Specific Membrane Antigen
Convergent Therapeutics, Inc. is a biotechnology company focused on developing next-generation targeted radiotherapies to treat cancer.